prof. dr. H.W. (Henderik Willem) Frijlink

Curriculum vitae: Henderik W. Frijlink

Affiliation

Department of Pharmaceutical Technology and Biopharmacy,

University of Groningen, The Netherlands.

Education/Career summary

Dr. Frijlink received his pharmaceutical training at the University of Groningen (The Netherlands), where he received his Ph.D. degree in Pharmaceutical Technology. He served for two years as a pharmacist in the Martini Hospital (Groningen, Nl). From 1992 to 1997 he was head of the Pharmaceutical Development Department of Solvay Pharmaceuticals. Since 1998 Dr. Frijlink is Professor and Chairman of the Department of Pharmaceutical Technology and Biopharmacy at the Groningen University Institute for Drug Exploration. The main interests of his current research are technical and biopharmaceutical aspects of pulmonary drug delivery and the development of dry powder inhalers. The formulation of biopharmaceuticals such as peptides, proteins, vaccines and gene based products using stabilizing sugar glasses is a further research topic in his department. He is interested in solid oral dosage forms, their technological and biopharmaceutical aspects and gastro-intestinal targeting strategies. Finally, he is interested in development, scale up and quality aspects of pharmaceutical production.

From 2016 to 2022 Dr. Frijlink was Director of the Groningen Research Institute of Pharmacy

Qualifications

Pharm.D., Registered Teaching Pharmacist

Publications and patents

(Co-) author of more 350 original articles in peer reviewed journals in the field of pharmaceutical technology.

Dr. Frijlink is named as (co-)inventor in 22 patents in the field of pharmaceutical dosage forms and production processes.

Projects

Frijlink was project leader and/or participant in three Dutch Top Institute Pharma projects. He was the Principal Coordinating Investigator in the UniSec project. UniSec is a European consortium consisting of 3 academic partners, 5 National Health Institutes and 3 SMEs, devoted to the development of universal influenza vaccines. The project was funded from the 7th framework programme (HEALTH 2013.2.3.0-1) and was carried out between 2013 and 2018. Furthermore, Frijlink is participant in the “iABC” project, an EU Innovative Medicines Initiative (IMI) project, which is devoted to the development of inhalable antibiotics for patients with cystic fibrosis and bronchiectasis and he is participant in the “Novel virucidal drugs” project a Swiss synergy fund granted project.

Awards

Astellas Basic Science Award 2008-2009

Wubbo Ockels Award 2010

Utrecht University Award for Excellence in Pharmaceutical Research 2015

EJPB Most Cited Paper Award 2020 

University of Groningen Impact Innovator Excellence Award 2023

Dr. Saal van Zwanenberg Honorary price 2023

Grants, research support and royalties

In total (2000-2022): 52 Million €

Vocational Training

Pharmaceutical Degree, University of Groningen (NL), 1985

Registered Pharmacist, University of Groningen (NL) 1990

Ph.D. Pharmaceutical Technology, University of Groningen (NL) 1990

Professional experience

1983-1985: Teaching assistant University of Groningen (NL)

1986-1990: Ph. D. student University of Groningen (NL)

1990: Post-doc researcher University of Groningen (NL)

1990-1992: Pharmacist, Martini Hospital Groningen (NL)

1992-1997: Head, Dosage Form Development Department EU, Solvay Pharmaceuticals

1998-present: Chairman of the Department of Pharmaceutical Technology and Biopharmacy, University of Groningen (NL)

2016-2022: Director of the Groningen Research Institute of Pharmacy, University of Groningen (NL)

PhD theses (co-)supervised

Up to 2022 Frijlink supervised 49 PhD projects